CClinicalTrials.gg
CompletedNCT03411044Updated Nov 5, 2024Results posted

Fitmore Hip Stem PMCF Study: A Multi-centre, Non-comparative, Prospective Post-market Clinical Follow-up Study.

An observational study in Osteoarthritis, Avascular Necrosis and Rheumatoid Arthritis, sponsored by Zimmer Biomet. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Zimmer Biomet · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
420
Ages
18 Years and older
Sex
All
01

Study summary

A multi-centre, non-comparative, prospective post-market clinical follow-up study to obtain survival, clinical and radiographic outcomes data on the Zimmer Fitmore Hip Stem.

Read the detailed description

The objective of this post market surveillance study is to obtain outcome data on the Fitmore Hip Stem by analysis of standard scoring systems, radiographs and adverse event records, and thus to assess the long-term performance and safety of this implant.

The Fitmore Hip Stem is a short and curved uncemented stem that allows preservation of the greater trochanter and of the gluteal muscles.

Indication/Target Population: Patients suffering from severe hip pain and disability requiring total hip arthroplasty.

Study Design: A multi-centre, non-comparative, prospective post-marketing study.

Targeted Number of Subjects: 500. Data Collection: Collection of preoperative, intra-operative and immediate post-operative data; follow-up visits at 6-12 weeks, 1, 2, 3, 5, 7 and 10 years post-operatively.

Recruitment period: 24 months. Clinical Assessments: Evaluations will be made using the Harris Hip Score, the Oxford Hip Score, the SF-12 Physical and Mental Health summary measures, the EQ-5D (EuroQol) and radiographically.

Safety Assessments: Safety will be assessed by appropriate recording and reporting of adverse events throughout the study. The Fitmore Hip Stem is CE marked, commercially available and has been pre-clinically tested.

02

Conditions studied

  • Osteoarthritis
  • Avascular Necrosis
  • Rheumatoid Arthritis
  • Prosthesis Failure

Keywords

  • Total Hip Arthroplasty
  • Fitmore
  • Minimal Invasive Surgery
  • Short Stem
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients suffering from severe hip pain and disability requiring hip surgery using the Fitmore Hip Stem, who meet all of the inclusion criteria and none of the exclusion criteria.

Inclusion criteria

  • Patients who are capable of understanding the doctor"s explanations, following his instructions and who are able to participate in the follow-up program.
  • Patients who have given written consent to take part in the study by signing the "Patient Consent Form".
  • 18 years minimum.
  • Male and female.
  • Patients suffering from severe hip pain and disability requiring hip surgery or as indicated in the treatment of a fracture.

Exclusion criteria

Exclusion Criteria:

  • Patients who are unwilling or unable to give consent or to comply with the follow-up program.
  • Pregnancy.
  • Patients who are skeletally immature.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
420 participants (actual)
Patient registry
No

Groups and cohorts

  • Subjects with a Fitmore Hip Stem

    Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and who received the Fitmore Hip Stem.

    Device: Fitmore Hip Stem

Interventions

  • DeviceFitmore Hip Stem
05

What researchers measure

Primary outcomes

  1. Harris Hip Score

    The Harris hip Score (HHS) is an outcome measure that includes a series of questions answered by the patient and physical examinations recorded by a qualified health care Professional. The HHS covers four domains: pain (one item, 0-44 points), function and functional activities (seven items, 0-47 points), absence of deformity (one item, 0-4 points) and range of motion (one item, 0-5 points). The total score can vary from a range of 0 - 100. The outcome score can be categorized as Excellent: 90-100; Good: 80-90; Fair: 70-80; Poor: \< 70.

    Time frame: Preop, 6 - 12 weeks, 1 year, 2 year, 3 year, 5 year, 7 and 10 years

  2. Radiographic Evaluations

    Radiographic evaluation was assessed at the time points listed below in order to identify potential adverse events.

    Time frame: 6 - 12 weeks and 7 years

  3. Survivorship

    The primary endpoint for this study is implant survival at 10 years which is assessed by revision of the Fitmore Hip Stem calculated using the Kaplan-Meier Survival Estimation. The survivorship with Kaplan-Meier (K-M) was calculated at 10 year for endpoint revision of any component.

    Time frame: 10 years post surgery

Secondary outcomes

  1. EQ5D

    The EuroQol 5 Dimension (EQ-5D) is a standardized Instrument widely used to measure health status. It is a self reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes 5 questions referring to mobility, selfcare, daily activities, pain/discomfort, and anxiety/depression. Each question can be answered in five ways, indicating no, slight, moderate, severe problems or inability to complete the task. The EQ-5D-5L score ranges from -0.59 to 1, where 1 is the best possible health state. The Visual Analogue Scale (VAS) is a vertical scale ranges from 100 ('The best health you can imagine') to 0 ('The worst health you can imagine') where the patient reports his/her self-rated health.

    Time frame: Preop, 6-12 weeks, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year and 10 Year

  2. SF-12 Physical and Mental Functional Scores

    The SF-12 is a multipurpose short-form (SF) generic measure of health status. It consists of twelve questions that measure eight health domains to assess physical and mental health. Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP). Mental health-related scales include Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH). Scores ranges from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: Preop, 6-12 Weeks, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year and 10 Year

  3. Oxford Hip Score

    The Oxford Hip Score (OHS) is a patient-reported outcome measure that was developed to specifically assess the patient's perspective of outcome following THA. The OHS consists of twelve questions covering function and pain associated with the hip. To calculate the total score, each response is scored from 0 (warst outcome) to 4 (best outcome) and the sum of all 12 items is reported with a maximum of 48, representing the best score possible. The Score ranges from 0 - 100 and the outcome score can be categorized as Excellent: \> 41; Good: 34 - 41; Fair: 27 - 33; Poor: \< 27.

    Time frame: Preop, 6-12 Weeks, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year and 10 Year

06

Results

Posted Oct 17, 2024
Limitations and caveats
Due to the COVID 19 pandemic, many study patients could not return for the 10 year follow up resulting to drop out. In addition, one study site which enrolled 80 cases could not continue to follow the study patients at the 7 year follow up due to lack of resources to continue the study.

Participant flow

Participant flow — Overall Study
MilestonePatients Suffering From Severe Hip Pain and Disability Requiring Total Hip Arthroplasty.
Started420
Completed230
Not completed190
Withdrew: Death30
Withdrew: Withdrawal by subject48
Withdrew: Lost to follow-up78
Withdrew: Adverse event30
Withdrew: Missing status4

Outcome measures

PrimaryHarris Hip Score

The Harris hip Score (HHS) is an outcome measure that includes a series of questions answered by the patient and physical examinations recorded by a qualified health care Professional. The HHS covers four domains: pain (one item, 0-44 points), function and functional activities (seven items, 0-47 points), absence of deformity (one item, 0-4 points) and range of motion (one item, 0-5 points). The total score can vary from a range of 0 - 100. The outcome score can be categorized as Excellent: 90-100; Good: 80-90; Fair: 70-80; Poor: \< 70.

Time frame:
Preop, 6 - 12 weeks, 1 year, 2 year, 3 year, 5 year, 7 and 10 years
Reported as:
Mean · score on a scale
Harris Hip Score
score on a scaleSubjects With a Fitmore Hip Stem
Preop50.0 ± 17.1
6 - 12 weeks80.6 ± 14.8
1 Year94.5 ± 8.0
2 Year94.5 ± 9.5
3 Year94.2 ± 10.0
5 Year93.5 ± 11.3
7 Year93.6 ± 11.2
10 Year92.6 ± 12.1
PrimaryRadiographic Evaluations

Radiographic evaluation was assessed at the time points listed below in order to identify potential adverse events.

Time frame:
6 - 12 weeks and 7 years
Reported as:
Number · participants
Radiographic Evaluations
participantsSubjects With a Fitmore Hip Stem
6 - 12 weeks2
7 Year1
PrimarySurvivorship

The primary endpoint for this study is implant survival at 10 years which is assessed by revision of the Fitmore Hip Stem calculated using the Kaplan-Meier Survival Estimation. The survivorship with Kaplan-Meier (K-M) was calculated at 10 year for endpoint revision of any component.

Time frame:
10 years post surgery
Reported as:
Number · percentage
Survivorship
percentageSubjects With a Fitmore Hip Stem
Survivorship96.85 (94.14 to 98.32)
SecondaryEQ5D

The EuroQol 5 Dimension (EQ-5D) is a standardized Instrument widely used to measure health status. It is a self reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes 5 questions referring to mobility, selfcare, daily activities, pain/discomfort, and anxiety/depression. Each question can be answered in five ways, indicating no, slight, moderate, severe problems or inability to complete the task. The EQ-5D-5L score ranges from -0.59 to 1, where 1 is the best possible health state. The Visual Analogue Scale (VAS) is a vertical scale ranges from 100 ('The best health you can imagine') to 0 ('The worst health you can imagine') where the patient reports his/her self-rated health.

Time frame:
Preop, 6-12 weeks, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year and 10 Year
Reported as:
Mean · score on a scale
EQ5D
score on a scaleSubjects With a Fitmore Hip Stem
Preop EQ-5D-5L0.4 ± 0.3
6 - 12 Weeks EQ-5D-5L0.8 ± 0.2
1 Year EQ-5D-5L0.9 ± 0.2
2 Year EQ-5D-5L0.9 ± 0.2
3 Year EQ-5D-5L0.9 ± 0.2
5 Year EQ-5D-5L0.9 ± 02
7 Year EQ-5D-5L0.9 ± 0.2
10 Year EQ-5D-5L0.9 ± 0.2
Preop VAS60.0 ± 19.0
6 - 12 Weeks VAS74.5 ± 14.6
1 Year VAS80.2 ± 14.3
2 Year VAS79.1 ± 16.6
3 Year VAS80.4 ± 15.3
5 Year VAS80.2 ± 15.0
7 Year VAS79.0 ± 16.2
10 Year VAS78.1 ± 16.3
SecondarySF-12 Physical and Mental Functional Scores

The SF-12 is a multipurpose short-form (SF) generic measure of health status. It consists of twelve questions that measure eight health domains to assess physical and mental health. Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP). Mental health-related scales include Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH). Scores ranges from 0 to 100, with higher scores indicating better physical and mental health functioning.

Time frame:
Preop, 6-12 Weeks, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year and 10 Year
Reported as:
Mean · score on a scale
SF-12 Physical and Mental Functional Scores
score on a scaleSubjects With a Fitmore Hip Stem
Preop SF-12 physical27.1 ± 9.6
6-12 Weeks SF-12 physical39.1 ± 9.5
1 Year SF-12 physical49.5 ± 8.6
2 Year SF-12 physical50.0 ± 9.1
3 Year SF-12 physical48.9 ± 9.2
5 Year SF-12 physical50.3 ± 8.7
7 Year SF-12 physical49.2 ± 9.3
10 Year SF-12 physical47.4 ± 10.5
Preop SF-12 Mental54.2 ± 9.6
6-12 Weeks SF-12 Mental56.6 ± 8.1
1 Year SF-12 Mental54.7 ± 7.3
2 Year SF-12 Mental55.1 ± 7.7
3 Year SF-12 Mental53.7 ± 8.2
5 Year SF-12 Mental53.0 ± 8.1
7 Year SF-12 Mental54.2 ± 8.7
10 Year SF-12 Mental54.2 ± 7.0
SecondaryOxford Hip Score

The Oxford Hip Score (OHS) is a patient-reported outcome measure that was developed to specifically assess the patient's perspective of outcome following THA. The OHS consists of twelve questions covering function and pain associated with the hip. To calculate the total score, each response is scored from 0 (warst outcome) to 4 (best outcome) and the sum of all 12 items is reported with a maximum of 48, representing the best score possible. The Score ranges from 0 - 100 and the outcome score can be categorized as Excellent: \> 41; Good: 34 - 41; Fair: 27 - 33; Poor: \< 27.

Time frame:
Preop, 6-12 Weeks, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year and 10 Year
Reported as:
Mean · score on a scale
Oxford Hip Score
score on a scaleSubjects With a Fitmore Hip Stem
Preop19.3 ± 8.1
6-12 Weeks36.2 ± 7.5
1 Year42.8 ± 7.4
2 Year43.5 ± 6.8
3 Year43.3 ± 6.8
5 Year43.0 ± 7.5
7 Year44.2 ± 6.4
10 Year43.7 ± 6.3

Adverse events

Collected over Operative, 6-12 weeks, 1, 2, 3, 5, 7, 10 years. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subjects With a Fitmore Hip Stem30/420 (7.1%)40/420 (9.5%)132/420 (31.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventSubjects With a Fitmore Hip Stem
Femoral PainMusculoskeletal and connective tissue disorders9/420
InfectionMusculoskeletal and connective tissue disorders8/420
Other Hip Related ComplicationMusculoskeletal and connective tissue disorders6/420
Heterotopic OssificationMusculoskeletal and connective tissue disorders4/420
Deep Vein ThrombosisMusculoskeletal and connective tissue disorders3/420
HematomaMusculoskeletal and connective tissue disorders3/420
Femoral Implant LooseningMusculoskeletal and connective tissue disorders2/420
Fracture of Femoral ShaftMusculoskeletal and connective tissue disorders2/420
Fracture of Femoral NeckMusculoskeletal and connective tissue disorders2/420
Fracture of TrochanterMusculoskeletal and connective tissue disorders2/420
Most frequent other events
Most frequent other events
EventSubjects With a Fitmore Hip Stem
Other General ComplicationMusculoskeletal and connective tissue disorders19/420
Other General ComplicationMusculoskeletal and connective tissue disorders19/420
Other Hip Related ComplicationGeneral disorders19/420
Other General ComplicationsGeneral disorders19/420
Other General ComplicationsGeneral disorders19/420
Other General ComplicationsGeneral disorders19/420
Other General ComplicationGeneral disorders18/420

Baseline characteristics

Patients suffering from severe hip pain and disability requiring hip surgery or as indicated in the treatment of a fracture.

Age, Categorical
Age, Categorical(Participants)Patients Suffering From Severe Hip Pain and Disability Requiring Total Hip Arthroplasty.
Study Population — <=18 years0
Study Population — Between 18 and 65 years420
Study Population — >=65 years0
Age, Continuous
Age, Continuous(Years)Patients Suffering From Severe Hip Pain and Disability Requiring Total Hip Arthroplasty.
Mean62.5 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Patients Suffering From Severe Hip Pain and Disability Requiring Total Hip Arthroplasty.
Female190
Male230
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Patients Suffering From Severe Hip Pain and Disability Requiring Total Hip Arthroplasty.
Region of Enrollment
Region of Enrollment(participants)Patients Suffering From Severe Hip Pain and Disability Requiring Total Hip Arthroplasty.
Italy70
United Kingdom80
Switzerland123
Germany147
07

Study locations

5 sites
  • Auguste Viktoria Klinik
    Bad Oeynhausen, 32545, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Clinica San Michele
    Albenga, 17031, Italy
  • Kantonsspital Graubünden
    Chur, 7000, Switzerland
  • The Yorkshire Clinic
    Bingley, West Yorkshire BD16 1TW, United Kingdom
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 2, 2010

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03411044
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jan 25, 2018
Start date
Feb 8, 2008
Primary completion
Jun 10, 2023
Completion
Jun 10, 2023
Results posted
Oct 17, 2024
Last update
Nov 5, 2024

Study contacts

Hassan Achakri
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion